Bone diseases

Li L et al. Clin Rheumatol 2018. doi: 10.1007/s10067-018-4185-0

Shin DE et al. Clinic Rev Bone Miner Metab 2018; Advance online publication. doi: 10.1007/s12018-018-9245-0

Vellucci R et al. Osteoporos Int 2018; Advance online publication. doi: 10.1007/s00198-018-4476-y

Singh L et al. Curr Osteoporos Rep 2018; Advance online publication. doi: 10.1007/s11914-018-0427-y

Lecka-Czernik B et al. Curr Osteoporos Rep 2018; Advance online publication. doi: 10.1007/s11914-018-0426-z

In this article, the authors briefly review the molecular mechanisms that lead to structural damage in ankylosing spondylitis and the impact of treatment with biologics to retard this process.

Magrey MN, Khan MA. Curr Rheumatol Rep 2017;19:17. doi:10.1007/s11926-017-0644-x

The authors provide an overview of transient osteoporosis of the hip, covering the epidemiology, pathophysiology, etiology, diagnosis, treatment, and potential complications of the condition.1

Asadipooya K, Graves L, Greene LW. Osteoporos Int 2017;28:1805–1816. doi:10.1007/s00198-017-3952-0

This paper analyzes the most promising new bone marker candidates and reviews the clinical utility of classical and novel markers for the management of postmenopausal osteoporosis.

Garnero P. Mol Diagn Ther 2017. doi:10.1007/s40291-017-0272-1

Alonso N, Calero-Paniagua I, del Pino-Montes J. Clinic Rev Bone Miner Metab 2017; 15: 37. doi: 10.1007/s12018-016-9226-0

The authors provide a concise overview of the pathogenesis of osteoporosis looking at where and how bone resorption occurs and questioning how fragility can be reduced.

Bone Disorders. Springer International Publishing Switzerland, 2017. doi:10.1007/978-3-319-29182-6_18

Mikosch gives a description of the clinical presentation of patients with osteoporosis to show the connection between clinical manifestations and their underlying cellular mechanisms.

Mikosch P. In: Principles of Osteoimmunology. Edited by Pietschmann P. Springer International Publishing Switzerland, 2016. doi:10.1007/978-3-319-34238-2_7